As demonstrated in the final analysis of CheckMate 067, patients who achieved at least 80% reduction in tumor size experienced long-term survival regardless of treatment with anti-CTL4 and anti-PD1 or anti-PD1 monotherapy (3). Here, SLC44A4 is linked to neoplasm.